# REGENXBIO Inc. (RGNX)

Source: https://www.quantisnow.com/company/RGNX
Generated: 2026-11-21T08:29:32.051Z

- Ticker: RGNX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2015
- SEC CIK: 0001590877
- Website: regenxbio.com

## About

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

## Latest RGNX news and filings

- 2026-11-10 14:10 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by REGENXBIO Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-regenxbio-inc-6783303)
- 2026-11-05 12:20 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by REGENXBIO Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-regenxbio-inc-6774629)
- 2026-11-05 12:10 UTC [SEC Form 8-K] [REGENXBIO Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/regenxbio-inc-filed-sec-form-8-k-results-of-operations-and-6774580)
- 2026-11-05 12:05 UTC [Earnings] [REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights](https://www.quantisnow.com/insight/regenxbio-reports-third-quarter-2026-financial-results-and-operational-highlights-6774497)
- 2026-11-03 21:33 UTC [SEC Form 4] [Chief Technology Officer Malzahn Craig was granted 27,777 shares, increasing direct ownership by 34% to 109,737 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-technology-officer-malzahn-craig-was-granted-27777-shares-increasing-6770144)
- 2026-11-03 21:32 UTC [SEC Form 4] [Chief Strategy & Legal Officer Christmas Patrick J. was granted 34,722 shares, increasing direct ownership by 17% to 240,690 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-strategy-legal-officer-christmas-patrick-j-was-granted-34722-6770132)
- 2026-11-03 21:31 UTC [SEC Form 4] [Chief Medical Officer Pakola Steve was granted 34,722 shares, increasing direct ownership by 17% to 240,263 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-pakola-steve-was-granted-34722-shares-increasing-6770127)
- 2026-11-03 21:31 UTC [SEC Form 4] [Chief Financial Officer Chan Mitchell was granted 24,305 shares, increasing direct ownership by 20% to 147,120 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-chan-mitchell-was-granted-24305-shares-increasing-6770113)
- 2026-11-03 12:05 UTC [Conference Announcement] [REGENXBIO to Participate in Stifel 2026 Healthcare Conference](https://www.quantisnow.com/insight/regenxbio-to-participate-in-stifel-2026-healthcare-conference-6768406)
- 2026-10-29 11:05 UTC [Earnings Date] [REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights](https://www.quantisnow.com/insight/regenxbio-to-host-conference-call-on-november-5-to-discuss-6762414)
- 2026-10-16 11:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by REGENXBIO Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-regenxbio-inc-6748645)
- 2026-10-13 17:37 UTC [SEC Form SCHEDULE 13G filed by REGENXBIO Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-regenxbio-inc-6744820)
- 2026-10-12 11:05 UTC [Conference Announcement] [REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20](https://www.quantisnow.com/insight/regenxbio-to-host-investor-event-highlighting-surabgene-lomparvovec-sura-vec-in-6743438)
- 2026-10-05 12:23 UTC [Analyst Coverage Initiated] [Mizuho initiated coverage on REGENXBIO with a new price target](https://www.quantisnow.com/insight/mizuho-initiated-coverage-on-regenxbio-with-a-new-price-target-6736079)
- 2026-09-24 23:17 UTC [REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting](https://www.quantisnow.com/insight/regenxbio-presents-positive-three-year-durability-data-for-surabgene-lomparvovec-in-6725830)
- 2026-09-23 20:05 UTC [SEC Form 8-K] [REGENXBIO Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement](https://www.quantisnow.com/insight/regenxbio-inc-filed-sec-form-8-k-entry-into-a-material-6724168)
- 2026-09-08 11:05 UTC [Conference Announcement] [REGENXBIO to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/regenxbio-to-participate-in-upcoming-investor-conferences-6707405)
- 2026-09-03 21:30 UTC [SEC Form 4] [Chief Technology Officer Malzahn Craig covered exercise/tax liability with 234 shares, decreasing direct ownership by 0.28% to 81,960 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-technology-officer-malzahn-craig-covered-exercisetax-liability-with-234-6705708)
- 2026-09-03 21:29 UTC [SEC Form 4] [Chief Financial Officer Chan Mitchell covered exercise/tax liability with 4,902 shares, decreasing direct ownership by 4% to 122,815 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-chan-mitchell-covered-exercisetax-liability-with-4902-6705704)
- 2026-08-27 23:03 UTC [Insider Buy] [Director Ciongoli Gregory Austin was granted 15,432 shares and bought $949,381 worth of shares (102,603 units at $9.25) (SEC Form 4)](https://www.quantisnow.com/insight/director-ciongoli-gregory-austin-was-granted-15432-shares-and-bought-6697673)
- 2026-08-27 23:02 UTC [SEC Form 3] [SEC Form 3 filed by new insider Ciongoli Gregory Austin](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-ciongoli-gregory-austin-6697671)
- 2026-08-25 20:57 UTC [SEC Form 8-K] [REGENXBIO Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/regenxbio-inc-filed-sec-form-8-k-leadership-update-financial-statements-6694527)
- 2026-08-25 11:05 UTC [Leadership Update] [REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli](https://www.quantisnow.com/insight/regenxbio-strengthens-board-of-directors-with-appointment-of-greg-ciongoli-6693546)
- 2026-08-24 21:20 UTC [SEC Form 8-K] [REGENXBIO Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/regenxbio-inc-filed-sec-form-8-k-regulation-fd-disclosure-other-6693110)
- 2026-08-24 11:05 UTC [REGENXBIO Announces Regulatory Update on RGX-121 for MPS II](https://www.quantisnow.com/insight/regenxbio-announces-regulatory-update-on-rgx-121-for-mps-ii-6692065)
- 2026-08-07 12:23 UTC [Analyst Downgrade] [REGENXBIO downgraded by Barclays with a new price target](https://www.quantisnow.com/insight/regenxbio-downgraded-by-barclays-with-a-new-price-target-6670720)
- 2026-08-06 11:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by REGENXBIO Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-regenxbio-inc-6667231)
- 2026-08-06 11:10 UTC [SEC Form 8-K] [REGENXBIO Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/regenxbio-inc-filed-sec-form-8-k-results-of-operations-and-6667215)
- 2026-08-06 11:05 UTC [Public Offering] [REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights](https://www.quantisnow.com/insight/regenxbio-reports-second-quarter-2026-financial-results-and-operational-highlights-6667175)
- 2026-08-04 20:30 UTC [SEC Form 4] [Chief Medical Officer Pakola Steve covered exercise/tax liability with 7,468 shares, decreasing direct ownership by 4% to 205,541 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-pakola-steve-covered-exercisetax-liability-with-7468-6662631)
- 2026-08-04 20:29 UTC [SEC Form 4] [Chief Strategy & Legal Officer Christmas Patrick J. covered exercise/tax liability with 4,699 shares, decreasing direct ownership by 2% to 205,968 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-strategy-legal-officer-christmas-patrick-j-covered-exercisetax-liability-6662565)
- 2026-08-03 11:05 UTC [Earnings Date] [REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights](https://www.quantisnow.com/insight/regenxbio-to-host-conference-call-on-august-6-to-discuss-6658650)
- 2026-07-20 11:34 UTC [SEC Form 8-K] [SEC Form 8-K filed by REGENXBIO Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-regenxbio-inc-6641891)
- 2026-07-18 18:55 UTC [REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting](https://www.quantisnow.com/insight/regenxbio-presents-positive-long-term-data-for-surabgene-lomparvovec-in-wet-6641663)
- 2026-07-17 21:29 UTC [SEC Form 424B5] [SEC Form 424B5 filed by REGENXBIO Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-regenxbio-inc-6641471)
- 2026-07-17 11:00 UTC [Public Offering] [REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants](https://www.quantisnow.com/insight/regenxbio-announces-pricing-of-public-offering-of-common-stock-and-6640475)
- 2026-07-17 01:54 UTC [SEC Form FWP] [SEC Form FWP filed by REGENXBIO Inc.](https://www.quantisnow.com/insight/sec-form-fwp-filed-by-regenxbio-inc-6640403)
- 2026-07-16 20:32 UTC [SEC Form 424B5] [SEC Form 424B5 filed by REGENXBIO Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-regenxbio-inc-6639895)
- 2026-07-16 20:26 UTC [Public Offering] [REGENXBIO Announces Proposed Public Offering of Common Stock](https://www.quantisnow.com/insight/regenxbio-announces-proposed-public-offering-of-common-stock-6639827)
- 2026-07-06 20:51 UTC [SEC Form 4] [Chief Executive Officer Simpson Curran was granted 2,404 shares and covered exercise/tax liability with 6,818 shares, decreasing direct ownership by 1% to 338,053 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-simpson-curran-was-granted-2404-shares-and-6628633)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/RGNX
- Earnings history: https://www.quantisnow.com/earnings/RGNX
- Dividend history: https://www.quantisnow.com/dividends/RGNX
- Insider transactions: https://www.quantisnow.com/insiders/RGNX
- Options chain: https://www.quantisnow.com/options/RGNX
- SEC 8-K filings only: https://www.quantisnow.com/company/RGNX/8-k
- RSS and alerts for RGNX: https://www.quantisnow.com/docs/rss-feeds.md
